Bioventus (BVS) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bioventus (BVS) has outperformed MiMedx Group (MDXG) over the past year, gaining 87.7% versus a loss of 34.9%. Over five years, BVS leads with a -7.0% price change compared with -31.7% for MDXG. Bioventus is the larger company by market cap ($866.8 million vs $674.2 million), about 1.3 times the size.
On valuation, Bioventus trades at a lower forward P/E (13.8x vs 23.1x for MiMedx Group).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | MDXG |
|---|---|---|
| Share price | $12.69 | $4.62 |
| Market cap | $866.79M | $674.22M |
| 1-day change | -0.63% | +0.22% |
| YTD return | +70.56% | -31.76% |
| 1-year return | +87.72% | -34.93% |
| 5-year return | -6.96% | -31.66% |
| P/E ratio (TTM) | 16.27 | 115.50 |
| Forward P/E | 13.79 | 23.10 |
| EPS (TTM) | $0.78 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $7.97 |
| 52-week low | $6.37 | $3.03 |
| Distance from 52-week high | -20.15% | -42.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +38.69% | +60.17% |
| Average volume | 614.83K | 1.23M |
| Shares outstanding | 68.31M | 145.93M |
| Employees | 950 | 808 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed MDXG by 122.7 percentage points over the past year.
- MiMedx Group trades at a higher earnings multiple (115.5x vs 16.3x trailing P/E).
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 950 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
BVS vs MDXG FAQ
Which is bigger, Bioventus or MiMedx Group?
Bioventus (BVS) is larger, with a market capitalization of $866.79M compared with $674.22M for MiMedx Group (MDXG).
Which stock has performed better over the past year, BVS or MDXG?
BVS returned +87.72% over the past 12 months, compared with -34.93% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BVS or MDXG?
BVS has the lower trailing P/E at 16.3, versus 115.5 for MDXG. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bioventus and MiMedx Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.